NMTC:NASDAQNeuroOne Medical Technologies Corporation Analysis

NeuroOne Medical Technologies (NMTC) is trading at $4.84, just above its 20‑day SMA of 4.60 and comfortably below the 200‑day SMA of 4.75, indicating a neutral trend with a slight bullish tilt. The RSI sits at 56.5, suggesting the stock is not overbought, while the MACD histogram turned positive (0.0077) and the MACD signal is labeled “bullish,” supporting modest upside momentum. Volatility is very high at ~65% over the past 30 days and beta is sub‑1 (0.74), meaning price swings are pronounced but less correlated with the market. Fundamentally, the company is distressed: negative operating margin (-59%), loss‑making EPS (-$1.08 trailing, -$0.28 forward), a sky‑high price‑to‑book ratio of 38.1, and a debt‑to‑equity of 3.7. The upside/downside metric shows a theoretical upside of 152%, and analysts’ median price target of $9.6 implies a ~98% upside from current levels. Recent material news includes a shareholder‑approved reverse stock split and an inducement grant to regain Nasdaq compliance, which may temporarily buoy liquidity but also signals ongoing listing risk.